Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPi-AKI Consortium Investigators. Gupta S, et al. Among authors: owen dh. J Immunother Cancer. 2021 Oct;9(10):e003467. doi: 10.1136/jitc-2021-003467. J Immunother Cancer. 2021. PMID: 34625513 Free PMC article.
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Abu-Sbeih H, et al. Among authors: owen dh. J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4. J Clin Oncol. 2020. PMID: 31800340 Free PMC article.
Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy.
Johns AC, Sorenson C, Rogers A, Agne JL, D'Souza DM, Das JK, Issa M, Perna G, Williams TM, Meara A, Kitchin T, Haglund KE, Owen DH. Johns AC, et al. Among authors: owen dh. Clin Lung Cancer. 2020 Jul;21(4):e243-e245. doi: 10.1016/j.cllc.2020.01.004. Epub 2020 Jan 27. Clin Lung Cancer. 2020. PMID: 32067849 Free PMC article. No abstract available.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR. Naqash AR, et al. Among authors: owen dh. Cancer Immunol Immunother. 2020 Jul;69(7):1177-1187. doi: 10.1007/s00262-020-02536-5. Epub 2020 Mar 5. Cancer Immunol Immunother. 2020. PMID: 32140762 Free PMC article.
Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations.
Baek J, Owen DH, Merritt RE, Shilo K, Otterson GA, D'Souza DM, Carbone DP, Kneuertz PJ. Baek J, et al. Among authors: owen dh. Clin Lung Cancer. 2020 Jul;21(4):e265-e269. doi: 10.1016/j.cllc.2020.02.016. Epub 2020 Feb 25. Clin Lung Cancer. 2020. PMID: 32184051 No abstract available.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR. Naqash AR, et al. Among authors: owen dh. Cancer Immunol Immunother. 2020 Jul;69(7):1189. doi: 10.1007/s00262-020-02582-z. Cancer Immunol Immunother. 2020. PMID: 32347358 Free PMC article.
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH. Spakowicz D, et al. Among authors: owen dh. BMC Cancer. 2020 May 6;20(1):383. doi: 10.1186/s12885-020-06882-6. BMC Cancer. 2020. PMID: 32375706 Free PMC article.
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, Miah A, Husain M, He K, Bertino EM, Shields PG, Wei L, Carbone DP, Otterson GA, Presley CJ, Owen DH. Li M, et al. Among authors: owen dh. Cancer Immunol Immunother. 2020 Nov;69(11):2403-2408. doi: 10.1007/s00262-020-02674-w. Epub 2020 Jul 29. Cancer Immunol Immunother. 2020. PMID: 32728772 Free PMC article.
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J. Shankar B, et al. JAMA Oncol. 2020 Dec 1;6(12):1952-1956. doi: 10.1001/jamaoncol.2020.5012. JAMA Oncol. 2020. PMID: 33119034 Free PMC article.
129 results